Movement Alert｜GenScript Biotech Rises 5.41% in Regular Trading, Recovering After Legend Biotech LB2501 Clinical Data Triggered Sell-the-News Pullback

Market Focus06-18

On June 18, GenScript Biotech rose 5.41% in regular trading, trading at HK$11.82/share, with turnover of HK$92.44 million. The stock is staging a recovery after pulling back more than 9% in prior sessions on a sell-the-news reaction.

On the news front, the company's associate Legend Biotech presented first-in-class in-vivo CD19/CD20 dual-target CAR-T therapy LB2501 Phase I proof-of-concept data at the European Hematology Association annual meeting on June 14. In the ongoing Phase I study for relapsed/refractory B-cell non-Hodgkin lymphoma, a single infusion of LB2501 achieved 100% objective response rate and 83.3% complete response rate at the second dose level, with all responses ongoing at data cutoff. Notably, LB2501 achieved dose-dependent in-vivo CAR-T cell expansion without lymphodepletion. The broader life sciences sector also strengthened, with Wuxi Biologics up 3.95%, Wuxi AppTec up 4.08%, and Insilico Medicine up 6.29%, providing additional sentiment support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196148161?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196148161","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GenScript Biotech Rises 5.41% in Regular Trading, Recovering After Legend Biotech LB2501 Clinical Data Triggered Sell-the-News Pullback","media":"Market Focus","content":"<p><p>On June 18, GenScript Biotech rose 5.41% in regular trading, trading at HK$11.82/share, with turnover of HK$92.44 million. The stock is staging a recovery after pulling back more than 9% in prior sessions on a sell-the-news reaction.</p><p>On the news front, the company's associate Legend Biotech presented first-in-class in-vivo CD19/CD20 dual-target CAR-T therapy LB2501 Phase I proof-of-concept data at the European Hematology Association annual meeting on June 14. In the ongoing Phase I study for relapsed/refractory B-cell non-Hodgkin lymphoma, a single infusion of LB2501 achieved 100% objective response rate and 83.3% complete response rate at the second dose level, with all responses ongoing at data cutoff. Notably, LB2501 achieved dose-dependent in-vivo CAR-T cell expansion without lymphodepletion. The broader life sciences sector also strengthened, with Wuxi Biologics up 3.95%, Wuxi AppTec up 4.08%, and Insilico Medicine up 6.29%, providing additional sentiment support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GenScript Biotech Rises 5.41% in Regular Trading, Recovering After Legend Biotech LB2501 Clinical Data Triggered Sell-the-News Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GenScript Biotech Rises 5.41% in Regular Trading, Recovering After Legend Biotech LB2501 Clinical Data Triggered Sell-the-News Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-18 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 18, GenScript Biotech rose 5.41% in regular trading, trading at HK$11.82/share, with turnover of HK$92.44 million. The stock is staging a recovery after pulling back more than 9% in prior sessions on a sell-the-news reaction.</p><p>On the news front, the company's associate Legend Biotech presented first-in-class in-vivo CD19/CD20 dual-target CAR-T therapy LB2501 Phase I proof-of-concept data at the European Hematology Association annual meeting on June 14. In the ongoing Phase I study for relapsed/refractory B-cell non-Hodgkin lymphoma, a single infusion of LB2501 achieved 100% objective response rate and 83.3% complete response rate at the second dose level, with all responses ongoing at data cutoff. Notably, LB2501 achieved dose-dependent in-vivo CAR-T cell expansion without lymphodepletion. The broader life sciences sector also strengthened, with Wuxi Biologics up 3.95%, Wuxi AppTec up 4.08%, and Insilico Medicine up 6.29%, providing additional sentiment support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1196148161","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196148161","pubTimestamp":1781749730,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 18, GenScript Biotech rose 5.41% in regular trading, trading at HK$11.82/share, with turnover of HK$92.44 million. The stock is staging a recovery after pulling back more than 9% in prior...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"动静提示|金斯瑞生物常规交易涨5.41%，在传奇生物LB2501临床数据引发抛售消息回调后恢复","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On June 18, GenScript Biotech rose 5.41% in regular trading, trading at HK$11.82/share, with turnover of HK$92.44 million. The stock is staging a recovery after pulling back more than 9% in prior sessions on a sell-the-news reaction.On the news front, the company's associate Legend Biotech presented first-in-class in-vivo CD19/CD20 dual-target CAR-T therapy LB2501 Phase I proof-of-concept data at the European Hematology Association annual meeting on June 14. In the ongoing Phase I study for relapsed/refractory B-cell non-Hodgkin lymphoma, a single infusion of LB2501 achieved 100% objective response rate and 83.3% complete response rate at the second dose level, with all responses ongoing at data cutoff. Notably, LB2501 achieved dose-dependent in-vivo CAR-T cell expansion without lymphodepletion. The broader life sciences sector also strengthened, with Wuxi Biologics up 3.95%, Wuxi AppTec up 4.08%, and Insilico Medicine up 6.29%, providing additional sentiment support.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196148161","isCrawlerRequest":true}